Lupin recalls over 51000 bottles of generic antibiotic Cefdinir for Oral Suspension in US
Written By : Ruchika Sharma
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2024-06-10 06:53 GMT | Update On 2024-06-20 18:39 GMT
Advertisement
Pharmaceutical company Lupin has declared the recall of more than 51,000 bottles of its generic antibiotic Cefdinir for Oral Suspension from the US market. This action stems from defective containers that lack proper seal integrity, prompting apprehensions regarding quality control protocols.
According to the US Food and Drug Administration (USFDA), the Baltimore-based arm of Lupin commenced the Class II recall for 51,006 bottles of the medication on May 8. A Class II recall typically occurs when there is a potential for temporary or medically reversible adverse health consequences.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.